BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer
NCT03627390
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Pancreatic Cancer
Unresectable Pancreatic Cancer
Interventions
DRUG:
BP-C1
DRUG:
BP-C2
Sponsor
Meabco A/S
Collaborators
[object Object]
[object Object]